Navigation Links
Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities
Date:4/22/2009

BELGRADE, April 22 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - HTDS chief scientist Dr. Sanja Pekovic provided updates from a recent medical convention held in Antwerpen; Joint Meeting 2009 Anatomische Gesellschaft - Nederlandse Anatomen Vereniging, Antwerpen, 27-30 March 2009.

Dr. Pekovic reported on the results of recent positive testing being conducted related to the CNS disorder multiple sclerosis and in suppression of reactive astrogliosis after brain injury. This led to a number of preliminary talks for future collaboration with other scientists working in the field. A more detailed review of the research results will be posted separately on the Pink Sheets as a supplementary filing shortly. Notably, this work was supported by the European Cooperation in the Field of Scientific and Technical Research (COST) organization.

Dr. Pekovic also reported the scientific team has started some in vitro studies of purine nucleoside analogues (ribavirin, tiazofurin, the drugs we are investigating) effects on microglial cell culture (there is no current data in the literature about their effect on microglia) in collaboration with professor Thomas Herdegen from Kiel University, Germany, who is also a member of COST as a representative of Germany. Over the last 3 months in the lab, our technicians have learned how to establish microglial cell culture, a valuable next step in the continued research.

HTDS will be providing additional funding to further this work, at the IBISS INSTITUT ZA BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC for Project 143005 headed by professor Mirjana Stojiljkovic.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New treatment shows promise against recurrent gynecologic cancers
2. Leading Critical Care Doctor Shifts From Treatment to Empowerment by Helping Americans Create Optimal Health in Their Lives
3. First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
4. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
5. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
6. Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells
7. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
8. For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
9. Targeted Treatments Show Mettle Against Advanced Cancers
10. North Carolina Give Kids A Smile! Project Treats Close to 20,000 Children
11. Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Super-Sod will attend ... 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show ... , For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Social media ... especially for hospitals and health systems. Smith & Jones’ delves into this insight and ... episode, President of Smith & Jones David Vener meets up with social media strategist ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a ... Medical University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, ... on Aging is a tremendous resource in our community. We are thrilled to participate ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 2017 Research and Markets has announced ... (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By Country ... ... forecasted to grow at a CAGR of 5.33% during 2016-2021 ... infectious diseases along with surging demand of digital thermometer. Apart from ...
(Date:2/22/2017)... Feb. 22, 2017 Oncternal Therapeutics, Inc., ... both rare and common malignancies, today announced the ... The company intends to use the proceeds to ... and to advance preclinical development of a new ... is a first-in-class anti-ROR1 monoclonal antibody being developed ...
(Date:2/22/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced that KCP-400 (RgIA4), a potent antagonist ... robust chronic pain relief and disease modifying effects ... the a9a10 nAChR as a new, non-opioid target ... were reported online in the February 20 th ...
Breaking Medicine Technology: